RPL23

Across TCGA pan-cancer cohorts, RPL23 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPL23 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RPL23 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL23 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

GBM, HNSC, and CCRCC are the cancer types where RPL23 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.245	0.476	<.001	18	view →
HNSC	DFS	Median	III,IV	0.921	0.665	.003	14	view →
CCRCC	OS	Tertile	All	0.659	1.000	.013	14	view →
LUAD	DFS	Median	All	0.984	0.823	.002	9	view →
OV	DFS	Median	All	0.685	0.923	.049	4	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
LSCC	OS	Median	All	0.773	1.000	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPL23–GBM (DFS)

Open the GBM breakdown →